Prospective study of adbelimumab combined with AG as first-line treatment for advanced pancreatic cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300077985

Enrollment

Unknown

Registered

2023-11-27

Start date

2023-11-27

Completion date

Unknown

Last updated

2023-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

experimental group:Adbelimumab combined with albumin-bound paclitaxel and gemcitabine

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: ? The pathological diagnosis was consistent with the diagnostic criteria of pancreatic cancer. ? Unresectable locally advanced or metastatic pancreatic cancer with pathological stage III-IV; ? patients with advanced pancreatic cancer who have not received systemic therapy; ?KPS score above 60; ? aged between 18 and 75 years old; ? the expected survival time is more than 3 months; ? The informed consent should be signed, and the process of obtaining informed consent should be in accordance with GCP regulations.

Exclusion criteria

Exclusion criteria: ? Severe primary cardiovascular disease, liver disease, renal disease, hematological disease; ? a history of severe autoimmune diseases; ? Laboratory tests before enrollment: blood routine: ANC1.5× upper limit of normal (UNL), serum creatinine clearance rate 1.5×UNL; ALT(SGPT) and AST(SGOT) >1.5×UNL

Design outcomes

Secondary

Measure	Time frame
Overall survival;Objective remission rate;Disease control rate;Safety;	—

Primary

Measure	Time frame
Progression free survival;	—

Countries

China

Contacts

Public ContactAnwei Dai

Kunshan Traditional Chinese Medicine Hospital

13962642809@163.com+86 139 6264 2809

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026